Lexicon pharmaceuticals, inc./de (LXRX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Net product revenue

7,877

-

8,351

8,672

6,740

-

6,286

7,316

5,460

-

5,830

3,892

721

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaborative agreements

8

-256,878

285,910

860

2,439

-209

556

6,404

19,832

-30,891

21,112

8,104

17,565

-60,181

27,686

20,001

12,494

-

505

338

-

21,482

312

627

172

1,376

238

211

284

218

214

199

152

320

335

461

516

632

1,164

Royalties and other revenue

114

137

187

150

37

71

124

78

82

114

0

57

7

36

31

88

0

-

61

38

-

0

107

49

105

34

0

3

76

0

158

0

148

23

20

94

80

149

69

Total revenues

7,999

8,727

294,448

9,682

9,216

17,071

6,966

13,798

25,374

34,401

26,942

12,053

18,293

18,956

27,717

20,089

12,494

127,280

566

376

1,792

21,482

419

676

277

1,410

238

214

360

218

372

199

300

343

355

555

596

781

1,233

Operating expenses:
Cost of sales (including finite-lived intangible asset amortization)

568

774

577

1,327

553

569

551

838

533

538

599

537

225

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development, including stock-based compensation of $2,176 and $1,768, respectively

55,181

40,606

26,659

12,637

12,022

12,307

13,763

26,477

47,696

42,571

39,137

26,934

43,581

26,222

52,533

48,216

37,002

30,442

23,111

20,769

20,865

20,031

24,108

21,187

23,953

20,263

25,400

23,692

20,327

20,990

19,192

19,355

23,037

28,107

19,655

20,145

23,921

18,941

20,239

Earnings Per Share, Diluted

-

-

1.95

-

-

-

-0.26

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative expenses, included stock-based compensation of $2,256 and $1,643, respectively

14,688

14,564

13,898

14,263

14,110

16,563

15,579

16,755

14,857

16,020

16,724

18,475

14,871

14,080

12,263

8,416

8,398

6,448

5,379

6,307

5,701

3,988

4,617

5,152

5,654

3,412

4,716

4,669

4,324

3,920

4,396

4,162

4,565

4,010

4,055

4,532

4,753

4,948

5,068

Increase in fair value of Symphony Icon, Inc. purchase liability

-

-

-

-

-

-

-

-

-

0

0

0

2,101

0

-2,146

478

965

782

3,404

-12

1,753

910

-1,072

448

1,142

-5,289

1,338

477

1,264

-200

5,844

2,162

2,081

1,568

2,336

1,804

1,058

1,145

0

Impairment loss on buildings

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,349

-

-

-

13,102

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

70,437

55,944

69,772

28,227

26,685

29,439

29,893

44,070

63,086

59,129

56,460

45,946

60,778

40,302

62,650

57,110

46,365

38,920

34,243

27,064

28,319

24,929

40,755

26,787

30,749

18,386

31,454

28,838

25,915

24,710

29,432

25,679

29,683

33,685

26,046

26,481

29,732

25,034

25,307

Loss from operations

-62,438

-47,217

224,676

-18,545

-17,469

-12,368

-22,927

-30,272

-37,712

-24,728

-29,518

-33,893

-42,485

-21,346

-34,933

-37,021

-33,871

88,360

-33,677

-26,688

-26,527

-3,447

-40,336

-26,111

-30,472

-16,976

-31,216

-28,624

-25,555

-24,492

-29,060

-25,480

-29,383

-33,342

-25,691

-25,926

-29,136

-24,253

-24,074

Gain on investments, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

53

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

39

44

53

55

44

58

56

40

60

68

87

51

200

Interest expense

5,131

5,191

5,204

5,164

5,117

5,225

5,252

5,187

5,113

2,163

1,619

1,614

1,588

1,634

1,646

1,638

1,649

1,678

1,687

1,655

1,702

892

449

455

457

477

492

496

506

520

527

530

537

551

560

810

607

637

729

Interest and other income, net

958

1,270

600

691

789

810

783

910

1,005

561

415

448

530

545

564

547

637

68

82

269

153

1,336

287

538

94

175

11

-4

34

84

4

21

-4

8

88

30

27

-2,700

-643

Net income (loss) before taxes

-

-

220,072

-

-

-

-27,396

-

-

-26,330

-30,722

-35,059

-43,543

-22,435

-36,015

-38,112

-34,883

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-27,539

-

Income tax benefit

-

-

-6,014

-

-

-

0

-

-

-4,048

0

0

-8,652

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax benefit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-26

-

Net loss

-66,611

-51,138

226,086

-23,018

-21,797

-16,783

-27,396

-34,549

-41,820

-22,321

-30,722

-35,059

-34,891

-22,435

-36,015

-38,112

-34,883

86,750

-35,282

-28,074

-28,076

-2,933

-40,498

-26,028

-30,835

-17,414

-31,658

-29,080

-25,974

-24,873

-29,539

-25,931

-29,868

-33,845

-26,103

-26,638

-29,629

-27,513

-25,193

Net loss per common share, Basic and Diluted

-0.63

-

2.13

-

-0.21

-

-0.26

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used in computing net loss per common share, Basic and Diluted

106,536

-

106,272

-

106,054

-

105,881

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per common share, basic and diluted

-

-

-

-0.22

-

-

-

-0.33

-0.40

-

-0.29

-0.33

-0.33

-0.21

-0.35

-0.37

-0.34

0.83

-0.34

-0.27

-0.27

-0.35

-0.55

-0.35

-0.06

-1.25

-0.06

-0.06

-0.05

-0.06

-0.06

-0.05

-0.06

-0.09

-0.08

-0.08

-0.09

-0.08

-0.07

Other comprehensive loss:
Unrealized gain on investments

776

48

-50

53

45

59

147

176

-172

-159

151

50

-69

-273

-258

39

516

-277

-40

75

86

-65

-3

-5

8

-36

7

-11

19

2

41

37

-78

-13

-37

31

35

-

-

Comprehensive loss

-65,835

-51,090

226,036

-22,965

-21,752

-16,724

-27,249

-34,373

-41,992

-22,480

-30,571

-35,009

-34,960

-22,708

-36,273

-38,073

-34,367

86,473

-35,322

-27,999

-27,990

-2,998

-40,501

-26,033

-30,827

-17,450

-31,651

-29,091

-25,955

-24,871

-29,498

-25,894

-29,946

-33,858

-26,140

-26,607

-29,594

-

-

Stock-based compensation expense associated with research and development expense

2,176

-

-

-

1,768

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense associated with selling, general and administrative expense

2,256

-

-

-

1,643

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)

-

-

28,638

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted Average Number of Shares Outstanding, Diluted

-

-

116,640

106,272

-

105,923

105,881

105,848

105,668

105,605

105,582

105,300

104,461

104,055

103,885

103,830

103,682

103,624

103,616

103,608

103,516

-355,627

73,542

73,518

513,955

-1,245,722

513,419

513,083

512,428

507,821

490,049

480,634

480,324

350,171

337,678

337,668

337,527

337,404

337,404